Your browser is no longer supported. Please, upgrade your browser.
Settings
TRIL Trillium Therapeutics Inc. daily Stock Chart
TRIL [NASD]
Trillium Therapeutics Inc.
Index- P/E- EPS (ttm)-2.90 Insider Own0.01% Shs Outstand100.71M Perf Week4.03%
Market Cap1.82B Forward P/E- EPS next Y-2.92 Insider Trans0.00% Shs Float76.07M Perf Month39.37%
Income- PEG- EPS next Q-0.90 Inst Own68.35% Short Float7.81% Perf Quarter87.46%
Sales0.12M P/S15841.96 EPS this Y-26.90% Inst Trans- Short Ratio2.52 Perf Half Y153.01%
Book/sh1.64 P/B11.02 EPS next Y28.10% ROA- Target Price11.02 Perf Year5580.78%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.29 - 20.96 Perf YTD1656.31%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-12.88% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low6196.55% ATR1.22
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)60.88 Volatility8.60% 7.61%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.47 Prev Close18.09
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.36M Price18.26
Recom1.50 SMA2010.86% SMA5022.40% SMA20099.70% Volume123,544 Change0.94%
Oct-12-20Initiated Evercore ISI Outperform
Sep-10-20Upgrade H.C. Wainwright Neutral → Buy $16.50
Aug-17-20Initiated Craig Hallum Buy $15
Jun-19-20Initiated Oppenheimer Outperform
May-26-20Initiated JMP Securities Mkt Outperform $10
Apr-13-18Resumed Leerink Partners Mkt Perform $7
Jul-17-17Initiated H.C. Wainwright Buy $7
Aug-03-16Initiated Ladenburg Thalmann Buy $18
May-15-15Initiated Oppenheimer Outperform $32
Apr-27-15Initiated Leerink Partners Outperform $29
Dec-01-20 05:03PM  
Nov-26-20 07:49AM  
Nov-25-20 07:00AM  
Nov-20-20 07:15AM  
Nov-16-20 07:00AM  
Nov-12-20 04:05PM  
Nov-08-20 10:00AM  
Nov-02-20 04:45PM  
04:15PM  
04:15PM  
Oct-12-20 09:47AM  
Oct-06-20 03:18PM  
Oct-05-20 07:00AM  
Oct-01-20 04:53PM  
Sep-30-20 11:01AM  
08:41AM  
Sep-29-20 04:34PM  
Sep-18-20 07:00AM  
Sep-16-20 04:05PM  
Sep-15-20 03:41PM  
08:38AM  
Sep-13-20 02:00PM  
07:28AM  
Sep-10-20 08:00PM  
02:23PM  
Sep-09-20 04:01PM  
08:34AM  
07:23AM  
04:50AM  
01:43AM  
Sep-08-20 04:56PM  
04:29PM  
04:05PM  
Sep-01-20 04:34PM  
Aug-12-20 07:00AM  
Jul-30-20 07:00AM  
Jul-20-20 10:11AM  
Jul-18-20 07:17PM  
Jul-06-20 07:00AM  
Jun-15-20 07:42AM  
Jun-01-20 06:02AM  
May-29-20 10:52AM  
08:00AM  
May-28-20 08:43AM  
May-15-20 05:00PM  
May-13-20 07:00AM  
May-06-20 07:00AM  
Apr-15-20 08:39AM  
Apr-08-20 07:00AM  
Apr-03-20 10:24AM  
Mar-30-20 09:20AM  
Mar-26-20 11:30AM  
Mar-10-20 09:29AM  
07:00AM  
Mar-02-20 09:08AM  
Feb-28-20 12:30PM  
Feb-10-20 05:54AM  
Feb-07-20 07:00AM  
Jan-31-20 07:20AM  
Jan-29-20 07:00AM  
Jan-23-20 08:15AM  
Jan-22-20 04:01PM  
Jan-16-20 08:00AM  
Jan-09-20 02:37PM  
Jan-07-20 08:30AM  
Jan-03-20 08:54AM  
Dec-22-19 05:10PM  
Nov-14-19 07:00AM  
Nov-08-19 11:31AM  
10:31AM  
Nov-06-19 07:00AM  
Oct-22-19 09:00AM  
Oct-08-19 07:00AM  
Sep-25-19 07:00AM  
Aug-13-19 07:00AM  
Jul-24-19 07:00AM  
Jul-02-19 07:00AM  
May-13-19 07:27AM  
07:00AM  
Apr-30-19 07:00AM  
Apr-15-19 07:00AM  
Apr-11-19 07:00AM  
Apr-08-19 07:00AM  
Apr-02-19 07:00AM  
Mar-27-19 05:00PM  
09:25AM  
Mar-11-19 06:10PM  
05:09PM  
Mar-08-19 06:37PM  
Feb-22-19 09:00AM  
Feb-21-19 04:00PM  
Dec-03-18 07:00AM  
Nov-14-18 07:00AM  
Sep-28-18 07:00AM  
Sep-27-18 07:00AM  
Sep-12-18 07:00AM  
Aug-30-18 09:30AM  
Aug-08-18 07:00AM  
Jun-19-18 06:30PM  
Jun-15-18 07:00AM  
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.